{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T11:04:35Z","timestamp":1789556675722,"version":"build-2803163510"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T00:00:00Z","timestamp":1744588800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T00:00:00Z","timestamp":1744588800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Impot Res"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1038\/s41443-025-01060-3","type":"journal-article","created":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T10:32:26Z","timestamp":1744626746000},"page":"641-646","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Hydroxyurea in the management of sickle cell disease-associated priapism: a scoping review"],"prefix":"10.1038","volume":"38","author":[{"given":"Aderonke Adelayo","family":"Badewa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6225-4244","authenticated-orcid":false,"given":"Wilton","family":"Fidelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6560-8605","authenticated-orcid":false,"given":"Arthur L.","family":"Burnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,14]]},"reference":[{"key":"1060_CR1","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1182\/blood-2006-12-061697","volume":"110","author":"J Villagra","year":"2007","unstructured":"Villagra J, Shiva S, Hunter LA, Machado RF, Gladwin MT, Kato GJ. Platelet activation in patients with sickle disease, hemolysis-associated pulmonary hypertension, and nitric oxide scavenging by cell-free hemoglobin. Blood. 2007;110:2166\u201372.","journal-title":"Blood"},{"key":"1060_CR2","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/j.1743-6109.2004.10117.x","volume":"1","author":"J Pryor","year":"2004","unstructured":"Pryor J, Akkus E, Alter G, Jordan G, Lebret T, Levine L, et al. Priapism. J Sex Med. 2004;1:116\u201320.","journal-title":"J Sex Med"},{"key":"1060_CR3","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1080\/03630269.2018.1452760","volume":"42","author":"GAO Arduini","year":"2018","unstructured":"Arduini GAO, Trov\u00f3 de Marqui AB. Prevalence and characteristics of priapism in sickle cell disease. Hemoglobin. 2018;42:73\u20137.","journal-title":"Hemoglobin"},{"key":"1060_CR4","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/S0140-6736(05)78941-8","volume":"351","author":"Alicia Ault","year":"1998","unstructured":"Ault Alicia. Hydroxyurea for the treatment of sickle cell disease US FDA approves first drug for sickle-cell anemia. Lancet. 1998;351:809.","journal-title":"Lancet"},{"key":"1060_CR5","doi-asserted-by":"publisher","first-page":"3551","DOI":"10.1182\/blood-2014-09-551887","volume":"125","author":"UA Anele","year":"2015","unstructured":"Anele UA, Le BV, Resar LMS, Burnett AL. How I treat priapism. Blood. 2015;125:3551\u20138.","journal-title":"Blood"},{"key":"1060_CR6","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1152\/physrev.1995.75.1.191","volume":"75","author":"KE Andersson","year":"1995","unstructured":"Andersson KE, Wagner G. Physiology of penile erection. Physiol Rev. 1995;75:191\u2013236.","journal-title":"Physiol Rev"},{"key":"1060_CR7","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1111\/j.1743-6109.04038.x","volume":"1","author":"I S\u00e1enz de Tejada","year":"2004","unstructured":"S\u00e1enz de Tejada I, Angulo J, Cellek S, Gonz\u00e1lez-Cadavid N, Heaton J, Pickard R, et al. Physiology of erectile function. J Sex Med. 2004;1:254\u201365.","journal-title":"J Sex Med"},{"key":"1060_CR8","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1002\/jcp.22195","volume":"224","author":"I Akinsheye","year":"2010","unstructured":"Akinsheye I, Klings ES. Sickle cell anemia and vascular dysfunction: the nitric oxide connection. J Cell Physiol. 2010;224:620\u20135.","journal-title":"J Cell Physiol"},{"key":"1060_CR9","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1002\/smrj.56","volume":"3","author":"UA Anele","year":"2015","unstructured":"Anele UA, Burnett AL. Nitrergic mechanisms for management of recurrent priapism. Sex Med Rev. 2015;3:160\u20138.","journal-title":"Sex Med Rev"},{"key":"1060_CR10","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1056\/NEJMct0708272","volume":"358","author":"OS Platt","year":"2008","unstructured":"Platt OS. Hydroxyurea for the treatment of sickle cell anemia. N Engl J Med. 2008;358:1362\u20139.","journal-title":"N Engl J Med"},{"key":"1060_CR11","doi-asserted-by":"publisher","first-page":"4002","DOI":"10.1182\/bloodadvances.2019000883","volume":"3","author":"AT Farrell","year":"2019","unstructured":"Farrell AT, Panepinto J, Desai AA, Kassim AA, Lebensburger J, Walters MC, et al. End points for sickle cell disease clinical trials: renal and cardiopulmonary, cure, and low-resource settings. Blood Adv. 2019;3:4002\u201320.","journal-title":"Blood Adv"},{"key":"1060_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/srep29361","volume":"6","author":"ME Huang","year":"2016","unstructured":"Huang ME, Facca C, Fatmi Z, Baille D, Benakli S, Vernis L. DNA replication inhibitor hydroxyurea alters Fe-S centers by producing reactive oxygen species in vivo. Sci Rep. 2016;6:29361.","journal-title":"Sci Rep"},{"key":"1060_CR13","first-page":"15","volume":"34","author":"S Charache","year":"1997","unstructured":"Charache S. Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults. Semin Hematol. 1997;34:15\u201321.","journal-title":"Semin Hematol"},{"key":"1060_CR14","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1172\/JCI200316672","volume":"111","author":"VP Cokic","year":"2003","unstructured":"Cokic VP, Smith RD, Beleslin-Cokic BB, Njoroge JM, Miller JL, Gladwin MT, et al. Hydroxyurea induces fetal hemoglobin by the nitric oxide\u2013dependent activation of soluble guanylyl cyclase. J Clin Invest. 2003;111:231\u20139.","journal-title":"J Clin Invest"},{"key":"1060_CR15","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1007\/s11255-014-0737-7","volume":"46","author":"UA \u200cAnele","year":"2014","unstructured":"\u200cAnele UA, Mack AK, Resar LMS, Burnett AL. Hydroxyurea therapy for priapism prevention and erectile function recovery in sickle cell disease: a case report and review of the literature. Int Urol Nephrol. 2014;46:1733\u20136.","journal-title":"Int Urol Nephrol"},{"key":"1060_CR16","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1124\/jpet.116.235473","volume":"359","author":"FH Silva","year":"2016","unstructured":"Silva FH, Karakus S, Musicki B, Matsui H, Bivalacqua TJ, Dos Santos JL, et al. Beneficial effect of the nitric oxide donor compound 3-(1,3-Dioxoisoindolin-2-yl)benzyl nitrate on dysregulated phosphodiesterase 5, NADPH oxidase, and nitrosative stress in the sickle cell mouse penis: implication for priapism treatment. J Pharm Exp Ther. 2016;359:230\u20137.","journal-title":"J Pharm Exp Ther"},{"key":"1060_CR17","doi-asserted-by":"publisher","first-page":"e0292706","DOI":"10.1371\/journal.pone.0292706","volume":"18","author":"DA Pereira","year":"2023","unstructured":"Pereira DA, Pereira DA, da Silva Pereira P, Silveira THR, Calmasini FB, Reis LO, et al. Hydroxyurea does not reverse functional alterations of the nitric oxide-cGMP pathway associated with priapism phenotype in corpus cavernosum from sickle cell mouse. PLoS One. 2023;18:e0292706.","journal-title":"PLoS One"},{"key":"1060_CR18","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1097\/00005392-199805000-00065","volume":"159","author":"AH Al Jam\u2019a","year":"1998","unstructured":"Al Jam\u2019a AH, Al Dabbous IA. Hydroxyurea in the treatment of sickle cell associated priapism. J Urol. 1998;159:1642\u20132.","journal-title":"J Urol"},{"key":"1060_CR19","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1182\/hematology.2022000380","volume":"2022","author":"IM Idris","year":"2022","unstructured":"Idris IM, Burnett AL, DeBaun MR. Epidemiology and treatment of priapism in sickle cell disease. Hematol Am Soc Hematol Educ Program. 2022;2022:450\u20138.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"1060_CR20","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1097\/JU.0000000000001365","volume":"205","author":"LT Hou","year":"2021","unstructured":"Hou LT, Burnett AL. Regimented phosphodiesterase type 5 inhibitor use reduces emergency department visits for recurrent ischemic priapism. J Urol. 2021;205:545\u201353.","journal-title":"J Urol"},{"key":"1060_CR21","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1002\/ajh.20142","volume":"77","author":"STO Saad","year":"2004","unstructured":"Saad STO, Lajolo C, Gilli S, Marques FC, Lima CS, Costa FF, et al. Follow-up of sickle cell disease patients with priapism treated by hydroxyurea. Am J Hematol. 2004;77:45\u20139.","journal-title":"Am J Hematol"},{"key":"1060_CR22","first-page":"518","volume":"66","author":"B Morrison","year":"2017","unstructured":"Morrison B, Hamilton P, Reid M. Effect of hydroxyurea on priapism in men with sickle cell disease. West Indian Med J. 2017;66:518\u201320.","journal-title":"West Indian Med J"},{"key":"1060_CR23","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1182\/blood-2023-190396","volume":"142","author":"IM Idris","year":"2023","unstructured":"Idris IM, Yusuf AA, Ismail I, Borodo AM, Musangedu K, Aliyu T, et al. Randomized controlled double-blind feasibility trial of tadalafil with hydroxyurea versus hydroxyurea with placebo for secondary prevention of recurrent priapism in men with sickle cell anemia: PIN trial final results. Blood. 2023;142:2531.","journal-title":"Blood"},{"key":"1060_CR24","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1182\/bloodadvances.2019001142","volume":"4","author":"MR DeBaun","year":"2020","unstructured":"DeBaun MR, Jordan LC, King AA, Schatz J, Vichinsky E, Fox CK, et al. American Society of Hematology 2020 guidelines for sickle cell disease: prevention, diagnosis, and treatment of cerebrovascular disease in children and adults. Blood Adv. 2020;4:1554\u201388.","journal-title":"Blood Adv"},{"key":"1060_CR25","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s12288-013-0261-4","volume":"30","author":"RK Agrawal","year":"2014","unstructured":"Agrawal RK, Patel RK, Shah V, Nainiwal L, Trivedi B. Hydroxyurea in sickle cell disease: drug review. Indian J Hematol Blood Transfus. 2014;30:91\u20136.","journal-title":"Indian J Hematol Blood Transfus"},{"key":"1060_CR26","doi-asserted-by":"publisher","first-page":"5300","DOI":"10.1182\/blood-2009-04-146852","volume":"115","author":"RE Ware","year":"2010","unstructured":"Ware RE. How I use hydroxyurea to treat young patients with sickle cell anemia. Blood. 2010;115:5300\u201311.","journal-title":"Blood"},{"key":"1060_CR27","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1517\/14740338.2015.1088827","volume":"14","author":"PT McGann","year":"2015","unstructured":"McGann PT, Ware RE. Hydroxyurea therapy for sickle cell anemia. Expert Opin Drug Saf. 2015;14:1749\u201358.","journal-title":"Expert Opin Drug Saf"},{"key":"1060_CR28","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1111\/j.1445-5994.2006.01290.x","volume":"37","author":"A Grigg","year":"2007","unstructured":"Grigg A. Effect of hydroxyurea on sperm count, motility and morphology in adult men with sickle cell or myeloproliferative disease. Intern Med J. 2007;37:190\u20132.","journal-title":"Intern Med J"}],"container-title":["International Journal of Impotence Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41443-025-01060-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41443-025-01060-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41443-025-01060-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T10:09:24Z","timestamp":1789553364000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41443-025-01060-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,14]]},"references-count":28,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1060"],"URL":"https:\/\/doi.org\/10.1038\/s41443-025-01060-3","relation":{},"ISSN":["0955-9930","1476-5489"],"issn-type":[{"value":"0955-9930","type":"print"},{"value":"1476-5489","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,14]]},"assertion":[{"value":"19 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Arthur L. Burnett is a consultant for Novartis Pharmaceuticals. Aderonke Badewa and Wilton Fidelis do not have any competing interests to disclose at this time.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}